PST-611 is a first in class non-viral vectorized therapy for the treatment of dry age-related macular degeneration (AMD)/geographic atrophy (GA), expressing human transferrin, a highly potent iron ...

PST-611 is a first in class non-viral vectorized therapy for the treatment of dry age-related macular degeneration (AMD)/geographic atrophy (GA), expressing human transferrin, a highly potent iron ...

PulseSight Therapeutics Announces First Close of its Series A Financing to Fund Clinical Development of PST-611 in dry AMD PulseSight Therapeutics S.A.S Thu, Feb 13, 2025, 3:00 AM 3 min read ...

Shares in US biotech Iveric Bio have shot up after the company said its lead drug Zimura had slowed eyesight deterioration in patients with the dry form of age-related macular degeneration (AMD ...

Symptoms vary though as there are two types of AMD: dry AMD and wet AMD. "Dry AMD is very common with about 80% of people with AMD having this form," says Dr. Purnima Patel, an ophthalmologist at ...